MEDIROM Healthcare Technologies Inc. Announces Closing of Public Offering
MEDIROM Healthcare Technologies (NASDAQ: MRM) has closed its public offering of 2,860,000 American Depositary Shares at $1.75 per share, raising approximately $5 million in gross proceeds before deducting underwriting discounts and expenses. The company granted underwriters a 45-day option to purchase up to 429,000 additional shares for over-allotments. ThinkEquity serves as the sole book-running manager for the offering.
The company, which operates over 300 wellness salons across Japan, plans to use the proceeds for working capital and general corporate purposes, including potential investments, acquisitions, strategic collaborations to expand its customer base, and marketing of new services.
MEDIROM Healthcare Technologies (NASDAQ: MRM) ha concluso la sua offerta pubblica di 2.860.000 American Depositary Shares a $1,75 per azione, raccogliendo circa $5 milioni in proventi lordi prima di detrarre i costi di sottoscrizione e le spese. La società ha concesso agli underwriter un'opzione di 45 giorni per acquistare fino a 429.000 azioni aggiuntive per sovra-allocazioni. ThinkEquity funge da unico manager della book-running per l'offerta.
La società, che gestisce oltre 300 saloni del benessere in Giappone, prevede di usare i proventi per capitale circolante e scopi aziendali generali, inclusi potenziali investimenti, acquisizioni, collaborazioni strategiche per espandere la propria base clienti e marketing di nuovi servizi.
MEDIROM Healthcare Technologies (NASDAQ: MRM) ha cerrado su oferta pública de 2,860,000 American Depositary Shares a $1.75 por acción, recaudando aproximadamente $5 millones en ingresos brutos antes de deducir descuentos de suscripción y gastos. La compañía otorgó a los suscriptores una opción de 45 días para comprar hasta 429,000 acciones adicionales para sobreasignaciones. ThinkEquity actúa como el único gerente de book-running para la oferta.
La empresa, que opera más de 300 salones de bienestar en Japón, planea utilizar los ingresos para capital de trabajo y propósitos corporativos generales, incluidos inversiones potenciales, adquisiciones, colaboraciones estratégicas para ampliar su base de clientes y marketing de nuevos servicios.
MEDIROM Healthcare Technologies (NASDAQ: MRM)는 2,860,000개의 미국 예탁주식을 주당 $1.75에 공개로 발행하여 약 $5 백만의 총 수익을 올렸습니다. 이는 인수수수료와 비용을 차감하기 전의 금액입니다. 회사는 인수자에게 429,000주를 추가로 구매할 수 있는 45일 옵션을 부여했습니다. ThinkEquity는 이번 공모의 단독 북런닝 매니저로 있습니다.
이 회사는 일본 전역에 300개 이상의 웰니스 살롱을 운영하며, 이번 수익금을 운영 자본과 일반 기업 목적으로 사용할 계획입니다. 여기에는 잠재적 투자, 인수, 고객층 확대를 위한 전략적 협업 및 새로운 서비스 마케팅이 포함됩니다.
MEDIROM Healthcare Technologies (NASDAQ: MRM) a clôturé son offre publique de 2 860 000 American Depositary Shares au prix de 1,75 $ par action, levant environ 5 millions $ de revenus bruts avant déduction des réductions et des frais de souscription. La société a accordé aux souscripteurs une option de 45 jours pour acheter jusqu'à 429 000 actions supplémentaires en raison de surallocations. ThinkEquity est le seul gestionnaire de book-running pour l'offre.
L'entreprise, qui exploite plus de 300 salons de bien-être au Japon, prévoit d'utiliser les revenus pour le besoin en fonds de roulement et les objectifs d'entreprise généraux, notamment des investissements potentiels, des acquisitions, des collaborations stratégiques pour élargir sa base de clients et le marketing de nouveaux services.
MEDIROM Healthcare Technologies (NASDAQ: MRM) hat ihr öffentliches Angebot von 2.860.000 American Depositary Shares zu einem Preis von 1,75 $ pro Aktie abgeschlossen und dabei etwa 5 Millionen $ an Bruttoerlösen vor Abzug von Underwriting-Rabatten und -Kosten erzielt. Das Unternehmen räumte den Underwritern eine 45-tägige Option ein, bis zu 429.000 zusätzliche Aktien für Überallokationen zu erwerben. ThinkEquity fungiert als alleiniger Book-Running-Manager für das Angebot.
Das Unternehmen, das über 300 Wellness-Salons in Japan verfügt, plant, die Erlöse für Betriebskapital und allgemeine Unternehmenszwecke, einschließlich potenzieller Investitionen, Übernahmen, strategischer Kooperationen zur Erweiterung seiner Kundenbasis und Marketing neuer Dienstleistungen zu verwenden.
- Successful completion of $5 million capital raise
- Potential for expansion through acquisitions and strategic collaborations
- Strong retail presence with 300+ wellness salons across Japan
- Significant shareholder dilution through public offering
- Low offering price at $1.75 per share
- Additional dilution possible through 429,000 share over-allotment option
Insights
TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services, today announced the closing of its public offering of 2,860,000 American Depositary Shares at a public offering price of
MEDIROM intends to use the proceeds for working capital and general corporate purposes, which may include investments, acquisitions, or strategic collaborations to expand its customer base, as well as marketing of new services.
ThinkEquity is acting as sole book-running manager for the offering.
A registration statement on Form F-1 (File No. 333-281771) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) and became effective on December 9, 2024. This offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About MEDIROM Healthcare Technologies Inc.
MEDIROM, a holistic healthcare company, operates over 300 wellness salons across Japan, Re.Ra.Ku® being its leading brand, and provides healthcare services. In 2015, MEDIROM entered the health tech business and launched new healthcare programs using an on-demand training app called “Lav®”, which is developed by MEDIROM. MEDIROM also entered the device business in 2020 and has developed a smart tracker “MOTHER Bracelet®”. In 2023, MEDIROM launched REMONY, a remote monitoring system for corporate clients, and has received orders from a broad range of industries, including nursing care, transportation, construction, and manufacturing, among others. MEDIROM hopes that its diverse health-related product and service offerings will help it collect and manage healthcare data from users and customers and enable it to become a leader in big data in the healthcare industry. For more information, visit https://medirom.co.jp/en.
Forward-Looking Statements Regarding MEDIROM
Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about MEDIROM’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to MEDIROM’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause MEDIROM’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond MEDIROM’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects MEDIROM’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to MEDIROM’s operations, results of operations, growth strategy and liquidity.
Contact:
Investor Relations Team
E-mail: ir@medirom.co.jp
FAQ
How much did MEDIROM (MRM) raise in its December 2024 public offering?
What is the over-allotment option in MEDIROM's December 2024 offering?
How will MEDIROM use the proceeds from its 2024 public offering?
Who is the book-running manager for MEDIROM's 2024 public offering?